StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $2.32 | $2.32 | +0.00% | 0.1M |
| 05-12 | $2.28 | $2.33 | +2.19% | 0.1M |
| 05-13 | $2.33 | $2.32 | -0.43% | 0.0M |
| 05-14 | $2.32 | $2.33 | +0.43% | 0.1M |
| 05-15 | $2.29 | $2.26 | -1.31% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for LPCN.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for LPCN.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Q2 2023 2023-06-30 | Q1 2023 2023-03-31 | Annual 2022 2022-12-31 | Q3 2022 2022-09-30 |
|---|---|---|---|---|
Revenue | $54.99K | $54.99K | $500.00K | $500.00K |
Operating Income | $-8.29M | $-4.34M | $-12.12M | $-9.56M |
Net Income | $-7.42M | $-3.87M | $-10.76M | $-8.53M |
EPS (Diluted) | $-1.44 | $-0.76 | $-2.15 | $-1.72 |
Total Assets | $30.48M | $34.02M | $37.54M | $39.42M |
Total Liabilities | $1.93M | $2.06M | $1.91M | $1.78M |
Cash & Equivalents | $5.01M | $4.77M | $3.15M | $2.40M |
Free Cash Flow OCF − CapEx | $-7.24M | $-3.93M | $-12.10M | $-10.17M |
Shares Outstanding | 5.23M | 88.51M | 5.23M | 88.51M |
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.